PharmacoEconomicsHumansMultiple MyelomaLenalidomideDexamethasoneBortezomib
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data.
Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, Andrew Spencer, Zoe K McQuilten
Published: 202610.1007/s40273-025-01554-4
Abstract
BACKGROUND AND OBJECTIVE: Health technology assessments traditionally rely on clinical trial data, leaving uncertainties about real-world cost effectiveness. This post-market economic evaluation used registry data to estimate the real-world cost effe…
Preview only. Read the full abstract at the source